RU2016152150A - Ботулинический токсин для применения в лечении паратонии - Google Patents
Ботулинический токсин для применения в лечении паратонии Download PDFInfo
- Publication number
- RU2016152150A RU2016152150A RU2016152150A RU2016152150A RU2016152150A RU 2016152150 A RU2016152150 A RU 2016152150A RU 2016152150 A RU2016152150 A RU 2016152150A RU 2016152150 A RU2016152150 A RU 2016152150A RU 2016152150 A RU2016152150 A RU 2016152150A
- Authority
- RU
- Russia
- Prior art keywords
- botulinum toxin
- paratonia
- use according
- paragraphs
- dementia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (10)
1. Ботулинический токсин для применения в лечении паратонии.
2. Ботулинический токсин для применения по п. 1, где диагностировали, что балл PAI (средство оценки паратонии) для паратонии составляет ≥3.
3. Ботулинический токсин для применения по п. 1 или 2, где паратония поражает верхнюю и/или нижнюю конечность.
4. Ботулинический токсин для применения по любому из пп. 1-3, где паратония связана с когнитивным нарушением в результате болезни Альцгеймера (AD), сосудистой деменции (VaD), деменции с тельцами Леви (DLB), лобно-височной деменции (FTD), подкорковой сосудистой деменции (SVD) или деменции смешанного типа без дополнительных уточнений (NOS).
5. Ботулинический токсин для применения по любому из пп. 1-4, где ботулинический токсин вводят местно путем внутримышечной инъекции.
6. Ботулинический токсин для применения по любому из пп. 1-5, где ботулинический токсин вводят в количестве приблизительно от 10 до 700 единиц.
7. Ботулинический токсин для применения по любому из пп. 1-6, где ботулинический токсин выбран из группы, состоящей из ботулинического токсина типов A, B, C1, D, E, F, G и их смесей.
8. Ботулинический токсин для применения по п. 7, где ботулинический токсин представляет собой ботулинический токсин типа A.
9. Ботулинический токсин для применения по любому из пп. 1-8, где ботулинический токсин представляет собой ботулинический токсинный комплекс или нейротоксичный компонент ботулинического токсинного комплекса.
10. Способ лечения паратонии у пациента, где способ включает местное введение терапевтически эффективного количества ботулинического токсина в мышцу пациента.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14001978.7 | 2014-06-06 | ||
| EP14001978.7A EP2952205B1 (en) | 2014-06-06 | 2014-06-06 | Botulinum toxin for use in the treatment of paratonia |
| PCT/CA2015/000363 WO2015184528A1 (en) | 2014-06-06 | 2015-06-05 | Botulinum toxin for use in the treatment of paratonia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016152150A true RU2016152150A (ru) | 2018-07-09 |
| RU2016152150A3 RU2016152150A3 (ru) | 2019-03-06 |
| RU2700939C2 RU2700939C2 (ru) | 2019-09-24 |
Family
ID=50932948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016152150A RU2700939C2 (ru) | 2014-06-06 | 2015-06-05 | Ботулинический токсин для применения в лечении паратонии |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10098932B2 (ru) |
| EP (1) | EP2952205B1 (ru) |
| JP (1) | JP6608915B2 (ru) |
| KR (1) | KR20170007859A (ru) |
| CN (1) | CN106456709A (ru) |
| AU (1) | AU2015271668B2 (ru) |
| BR (1) | BR112016028402A2 (ru) |
| CA (1) | CA2948915C (ru) |
| ES (1) | ES2642916T3 (ru) |
| HK (1) | HK1218627A1 (ru) |
| HR (1) | HRP20171406T1 (ru) |
| IL (1) | IL249152B (ru) |
| PL (1) | PL2952205T3 (ru) |
| RU (1) | RU2700939C2 (ru) |
| WO (1) | WO2015184528A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102088104B1 (ko) * | 2018-06-29 | 2020-03-11 | 호서대학교 산학협력단 | 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물 |
| GB201815844D0 (en) * | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374896B2 (en) | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
| JP2005154407A (ja) * | 2003-06-20 | 2005-06-16 | Santen Pharmaceut Co Ltd | 筋緊張亢進性疾患の治療剤 |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| US20090324647A1 (en) * | 2005-10-11 | 2009-12-31 | Borodic Gary E | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| UA18308U (en) * | 2006-03-27 | 2006-11-15 | Serhii Valeriiovych Vlasenko | Method for correcting pathological neuro-orthopedic syndromes in patients with infantile cerebral paralysis |
| ES2322882B1 (es) * | 2006-10-25 | 2010-04-22 | Lipotec Sa | Peptidos inhibidores de la exocitosis neuronal. |
| FR2907680B1 (fr) * | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
| WO2009015840A2 (en) | 2007-07-27 | 2009-02-05 | Merz Pharma Gmbh & Co. Kgaa | Polypeptide for targeting of neural cells |
| SG2014009112A (en) | 2008-03-14 | 2014-04-28 | Allergan Inc | Immuno-based botulinum toxin serotype a activity assays |
| WO2010013494A1 (ja) * | 2008-07-31 | 2010-02-04 | 財団法人化学及血清療法研究所 | 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用 |
| CA2733283A1 (en) | 2008-08-29 | 2010-03-04 | Merz Pharma Gmbh & Co. Kgaa | Clostridial neurotoxins with altered persistency |
| KR102005930B1 (ko) * | 2008-12-31 | 2019-07-31 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
| EP2246065A1 (en) * | 2009-04-29 | 2010-11-03 | Merz Pharma GmbH & Co. KGaA | Intrastriatal botulinum toxin therapy |
| ES2693705T3 (es) | 2009-07-02 | 2018-12-13 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxinas que muestran actividad biológica reducida |
| RU2616281C2 (ru) | 2011-09-29 | 2017-04-13 | СЕЛЛСНЭП, ЭлЭлСи | Композиции и способы испытаний на токсикогенность |
| JP6162135B2 (ja) | 2011-11-09 | 2017-07-12 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | 短縮された生物活性を示す神経毒 |
-
2014
- 2014-06-06 ES ES14001978.7T patent/ES2642916T3/es active Active
- 2014-06-06 PL PL14001978T patent/PL2952205T3/pl unknown
- 2014-06-06 EP EP14001978.7A patent/EP2952205B1/en active Active
-
2015
- 2015-06-05 KR KR1020177000344A patent/KR20170007859A/ko not_active Application Discontinuation
- 2015-06-05 WO PCT/CA2015/000363 patent/WO2015184528A1/en active Application Filing
- 2015-06-05 CN CN201580029898.8A patent/CN106456709A/zh active Pending
- 2015-06-05 BR BR112016028402A patent/BR112016028402A2/pt not_active Application Discontinuation
- 2015-06-05 RU RU2016152150A patent/RU2700939C2/ru active
- 2015-06-05 US US15/316,324 patent/US10098932B2/en active Active
- 2015-06-05 AU AU2015271668A patent/AU2015271668B2/en active Active
- 2015-06-05 CA CA2948915A patent/CA2948915C/en active Active
- 2015-06-05 JP JP2017516010A patent/JP6608915B2/ja active Active
-
2016
- 2016-06-08 HK HK16106637.8A patent/HK1218627A1/zh unknown
- 2016-11-23 IL IL249152A patent/IL249152B/en active IP Right Grant
-
2017
- 2017-09-18 HR HRP20171406TT patent/HRP20171406T1/hr unknown
-
2018
- 2018-09-07 US US16/124,920 patent/US20190000937A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2952205A1 (en) | 2015-12-09 |
| CA2948915A1 (en) | 2015-12-10 |
| BR112016028402A2 (pt) | 2017-10-31 |
| WO2015184528A1 (en) | 2015-12-10 |
| EP2952205B1 (en) | 2017-08-09 |
| IL249152A0 (en) | 2017-01-31 |
| US20170143808A1 (en) | 2017-05-25 |
| HK1218627A1 (zh) | 2017-03-03 |
| CN106456709A (zh) | 2017-02-22 |
| US10098932B2 (en) | 2018-10-16 |
| IL249152B (en) | 2019-02-28 |
| KR20170007859A (ko) | 2017-01-20 |
| US20190000937A1 (en) | 2019-01-03 |
| PL2952205T3 (pl) | 2018-01-31 |
| JP6608915B2 (ja) | 2019-11-20 |
| AU2015271668B2 (en) | 2020-06-25 |
| JP2017516865A (ja) | 2017-06-22 |
| RU2700939C2 (ru) | 2019-09-24 |
| RU2016152150A3 (ru) | 2019-03-06 |
| ES2642916T3 (es) | 2017-11-20 |
| CA2948915C (en) | 2021-01-26 |
| HRP20171406T1 (hr) | 2017-12-15 |
| AU2015271668A1 (en) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| WO2018089508A3 (en) | Anti-cd47 antibodies | |
| EA201990226A1 (ru) | Способы и композиции для лечения миелофиброза | |
| MX2022008181A (es) | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. | |
| WO2016210372A3 (en) | Methods to treat neurological diseases | |
| MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| EA201892008A1 (ru) | Соединения и способы лечения неврологических и сердечно-сосудистых состояний | |
| EA201791993A1 (ru) | Способы лечения протеинопатий | |
| BR112017007063A2 (pt) | ?composições e métodos para o tratamento de insônia? | |
| DK3405215T3 (da) | Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| NZ741780A (en) | Anti-htra1 antibodies and methods of use thereof | |
| MX2019006495A (es) | Tratamiento de enfermedades neurologicas. | |
| EA201892638A1 (ru) | Специфический аналог трифторэтилхинолина для применения при лечении apids | |
| EA201492102A1 (ru) | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| RU2016152150A (ru) | Ботулинический токсин для применения в лечении паратонии | |
| BR112017023539A2 (pt) | composições para limpeza de cólon e tratamento de distúrbios gastrointestinais | |
| CY1124821T1 (el) | Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ | |
| EA202090194A1 (ru) | Композиции статинов и способы их применения при лечении синуклеинопатий | |
| MX2016008968A (es) | Compuestos organicos. | |
| MA39912A (fr) | Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. |